Shasqi is the first YC Bio company to start first-in-human clinical trials for a drug.</p>\n<p>We’re very excited to share <a href=https://www.ycombinator.com/"https://www.shasqi.com/news/2020/10/14/shasqi-announces-click-chemistry-breakthrough-with-first-ever-human-application-in-launch-of-clinical-program/">the news</a> that Shasqi is the first YC Bio company to have a drug enter first-in-human clinical trials<sup id=\"footnoteid1\"><a href=https://www.ycombinator.com/"#footnote1\">1</a></sup>. Shasqi is developing a novel therapy for cancer that allows a chemotherapy drug to be delivered much more precisely to the tumor. They dosed two cancer patients over the last couple of weeks and their Phase 1 trial’s enrollment is progressing well.</p>\n<p>Shasqi is the first therapeutics company YC funded, back in 2015 when we launched <a href=https://www.ycombinator.com/"https://www.ycombinator.com/library/4L-how-biotech-startup-funding-will-change-in-the-next-10-years/">YC Bio</a>.</p>\n<p>We started YC Bio because we believed that there were brilliant scientists who wanted to start life science companies, but struggled to find investors who would fund them to get started. We didn’t know him yet, but José Mejia Oneto, the founder of Shasqi, is exactly the kind of scientist we had in mind.</p>\n<p>José has an unusual background: he is both a PhD in organic chemistry and trained in orthopaedic surgery. The idea behind Shasqi draws on both fields, which is probably why Jose was uniquely positioned to see it.</p>\n<p>In 2014, José had just left his medical residency to pursue the idea for Shasqi. To learn the basics of starting a company, he watched YC’s Startup School talks. When he heard that YC had started funding biotech startups, he applied.</p>\n<p>During the YC program, José made incredibly rapid progress. In just three months, he was able to show in a breast cancer mouse model that his new treatment approach outperformed conventional chemo. Since then, we’ve watched Shasqi continue to operate at impressive speed, closing a seed round and then a Series A, and moving rapidly through preclinical studies.</p>\n<p>As exciting as it is for their first drug to enter clinical testing, Shasqi’s vision goes much further. Its core technology, Click Chemistry Activated Protodrug Against Cancer (CAPAC), is a true platform can be used beyond chemotherapies and small molecules, into peptides, antibodies, cytokines, and other types of cancer therapies &#8211; anytime you want a cancer drug at a specific area of the body. It is based on click chemistry, a powerful technique that is used widely in the lab but has not been used in humans before. In the future, Shasqi’s technology could underlie dozens of approved drugs.</p>\n<p>We couldn’t be more proud to have gotten to play a small role in helping Shasqi get started.</p>\n<p><strong>Notes</strong><br />\n<b id=\"footnote1\">1.</b> To be specific, other YC Bio companies have had drugs in human clinical trials through research IND’s and expanded access IND’s. Shasqi is the first to have a commercial IND, which is what is required to get a drug approved for general use.<a href=https://www.ycombinator.com/"#footnoteid1\">↩</a></p>\n<!--kg-card-end: html-->","comment_id":"1104510","feature_image":null,"featured":false,"visibility":"public","email_recipient_filter":"none","created_at":"2020-10-13T23:00:38.000-07:00","updated_at":"2021-10-20T10:52:26.000-07:00","published_at":"2020-10-13T23:00:38.000-07:00","custom_excerpt":null,"codeinjection_head":null,"codeinjection_foot":null,"custom_template":null,"canonical_url":null,"authors":[{"id":"61fe29e3c7139e0001a71097","name":"Jared Friedman","slug":"jared-friedman","profile_image":"/blog/content/images/2022/02/Jared.jpg","cover_image":null,"bio":"Jared is Managing Director, Software and Group Partner at YC. He was cofounder of Scribd, which was funded by Y Combinator in 2006 and grew to be one of the top 100 sites on the web.","website":null,"location":null,"facebook":null,"twitter":null,"meta_title":null,"meta_description":null,"url":"https://ghost.prod.ycinside.com/author/jared-friedman/"}],"tags":[{"id":"61fe29efc7139e0001a7117e","name":"Biotech","slug":"biotech","description":null,"feature_image":null,"visibility":"public","og_image":null,"og_title":null,"og_description":null,"twitter_image":null,"twitter_title":null,"twitter_description":null,"meta_title":null,"meta_description":null,"codeinjection_head":null,"codeinjection_foot":null,"canonical_url":null,"accent_color":null,"url":"https://ghost.prod.ycinside.com/tag/biotech/"}],"primary_author":{"id":"61fe29e3c7139e0001a71097","name":"Jared Friedman","slug":"jared-friedman","profile_image":"https://ghost.prod.ycinside.com/content/images/2022/02/Jared.jpg","cover_image":null,"bio":"Jared is Managing Director, Software and Group Partner at YC. He was cofounder of Scribd, which was funded by Y Combinator in 2006 and grew to be one of the top 100 sites on the web.","website":null,"location":null,"facebook":null,"twitter":null,"meta_title":null,"meta_description":null,"url":"https://ghost.prod.ycinside.com/author/jared-friedman/"},"primary_tag":{"id":"61fe29efc7139e0001a7117e","name":"Biotech","slug":"biotech","description":null,"feature_image":null,"visibility":"public","og_image":null,"og_title":null,"og_description":null,"twitter_image":null,"twitter_title":null,"twitter_description":null,"meta_title":null,"meta_description":null,"codeinjection_head":null,"codeinjection_foot":null,"canonical_url":null,"accent_color":null,"url":"https://ghost.prod.ycinside.com/tag/biotech/"},"url":"https://ghost.prod.ycinside.com/shasqi-first-in-human-clinical-trials/","excerpt":"Shasqi [http://shasqi.com] is the first YC Bio company to start first-in-human\nclinical trials for a drug.\n\nWe’re very excited to share the news\n[https://www.shasqi.com/news/2020/10/14/shasqi-announces-click-chemistry-breakthrough-with-first-ever-human-application-in-launch-of-clinical-program] \nthat Shasqi is the first YC Bio company to have a drug enter first-in-human\nclinical trials1. Shasqi is developing a novel therapy for cancer that allows a\nchemotherapy drug to be delivered much more pre","reading_time":2,"access":true,"og_image":null,"og_title":null,"og_description":null,"twitter_image":null,"twitter_title":null,"twitter_description":null,"meta_title":null,"meta_description":null,"email_subject":null,"frontmatter":null,"feature_image_alt":null,"feature_image_caption":null},"mentions":[],"related_posts":[{"id":"61fe29f1c7139e0001a71b68","uuid":"ec09b678-f338-4c3c-8afc-ad0295e0befd","title":"YC and Ginkgo Bioworks announce new partnership for synthetic biology startups","slug":"yc-and-ginkgo-bioworks-announce-new-partnership-for-synthetic-biology-startups","html":"<!--kg-card-begin: html--><p><a href=https://www.ycombinator.com/"https://www.ginkgobioworks.com//">Ginkgo Bioworks</a> was the first bio company YC funded, back in summer 2014, which makes us especially delighted to <a href=https://www.ycombinator.com/"https://www.ginkgobioworks.com/2019/09/16/building-a-platform-for-startups//">announce a new partnership between YC and Ginkgo.</p>\n<p>Ginkgo Bioworks programs cells. They program them to produce flavors, fragrances, cannabinoids, food proteins, and more. To do that, they have built the world’s most advanced compiler and debugger of genetic code for the rapid engineering of new organisms.</p>\n<p>Today, Ginkgo’s core business is programming cells for large companies like Bayer and Roche. But these are multi-million dollar deals that are out of the reach of startups. Ginkgo’s new deal will make it possible for startups to access the same platform.</p>\n<p>Ginkgo Bioworks will offer to program cells for YC companies doing qualifying synthetic biology projects on a $0 down basis. Instead of charging, Ginkgo will get equity. Their equity ownership will be based on achieving technical milestones, so it’s essentially a risk free deal for the companies. Ginkgo will effectively be making a big in-kind R&amp;D investment in these companies. Before engaging with YC companies, Ginkgo will need to vet the projects for technical feasibility and IP conflicts. But a broad range of projects will qualify, and I expect that the right companies can save years and millions of dollars by taking advantage of this deal.</p>\n<p>YC has funded many synthetic biology companies, working on products from industrial chemicals to food ingredients to cosmetics to therapeutics. In the past, companies like this had to make major investments upfront in organism engineering before they could manufacture anything. With this deal from Ginkgo, the next generation of synthetic biology companies will have the option to start by leveraging Ginkgo rather than building lab infrastructure in-house.</p>\n<p>Ginkgo providing startups access to their platform is a big step in the shift that we see towards the AWSification of biology. Ginkgo now joins YC companies like <a href=https://www.ycombinator.com/"https://www.culturebiosciences.com//">Culture Biosciences</a>, <a href=https://www.ycombinator.com/"https://www.atomwise.com//">Atomwise, and <a href=https://www.ycombinator.com/"https://excepgen.com//">Excepgen that are making it possible for bio companies to use existing building blocks rather than doing everything from scratch. As this trend accelerates, it will become faster and cheaper for new bio companies to get started.</p>\n<!--kg-card-end: html-->","comment_id":"1103931","feature_image":null,"featured":false,"visibility":"public","email_recipient_filter":"none","created_at":"2019-09-15T23:00:00.000-07:00","updated_at":"2021-10-20T10:53:35.000-07:00","published_at":"2019-09-15T23:00:00.000-07:00","custom_excerpt":null,"codeinjection_head":null,"codeinjection_foot":null,"custom_template":null,"canonical_url":null,"authors":[{"id":"61fe29e3c7139e0001a71097","name":"Jared Friedman","slug":"jared-friedman","profile_image":"/blog/content/images/2022/02/Jared.jpg","cover_image":null,"bio":"Jared is Managing Director, Software and Group Partner at YC. He was cofounder of Scribd, which was funded by Y Combinator in 2006 and grew to be one of the top 100 sites on the web.","website":null,"location":null,"facebook":null,"twitter":null,"meta_title":null,"meta_description":null,"url":"https://ghost.prod.ycinside.com/author/jared-friedman/"}],"tags":[{"id":"61fe29efc7139e0001a7117e","name":"Biotech","slug":"biotech","description":null,"feature_image":null,"visibility":"public","og_image":null,"og_title":null,"og_description":null,"twitter_image":null,"twitter_title":null,"twitter_description":null,"meta_title":null,"meta_description":null,"codeinjection_head":null,"codeinjection_foot":null,"canonical_url":null,"accent_color":null,"url":"https://ghost.prod.ycinside.com/tag/biotech/"},{"id":"61fe29efc7139e0001a71173","name":"YC News","slug":"yc-news","description":null,"feature_image":null,"visibility":"public","og_image":null,"og_title":null,"og_description":null,"twitter_image":null,"twitter_title":null,"twitter_description":null,"meta_title":null,"meta_description":null,"codeinjection_head":null,"codeinjection_foot":null,"canonical_url":null,"accent_color":null,"url":"https://ghost.prod.ycinside.com/tag/yc-news/"}],"primary_author":{"id":"61fe29e3c7139e0001a71097","name":"Jared Friedman","slug":"jared-friedman","profile_image":"https://ghost.prod.ycinside.com/content/images/2022/02/Jared.jpg","cover_image":null,"bio":"Jared is Managing Director, Software and Group Partner at YC. He was cofounder of Scribd, which was funded by Y Combinator in 2006 and grew to be one of the top 100 sites on the web.","website":null,"location":null,"facebook":null,"twitter":null,"meta_title":null,"meta_description":null,"url":"https://ghost.prod.ycinside.com/author/jared-friedman/"},"primary_tag":{"id":"61fe29efc7139e0001a7117e","name":"Biotech","slug":"biotech","description":null,"feature_image":null,"visibility":"public","og_image":null,"og_title":null,"og_description":null,"twitter_image":null,"twitter_title":null,"twitter_description":null,"meta_title":null,"meta_description":null,"codeinjection_head":null,"codeinjection_foot":null,"canonical_url":null,"accent_color":null,"url":"https://ghost.prod.ycinside.com/tag/biotech/"},"url":"https://ghost.prod.ycinside.com/yc-and-ginkgo-bioworks-announce-new-partnership-for-synthetic-biology-startups/","excerpt":"Ginkgo Bioworks was the first bio company YC funded, back in summer 2014, which makes us especially delighted to announce a new partnership between YC and Ginkgo.","reading_time":1,"access":true,"og_image":null,"og_title":null,"og_description":null,"twitter_image":null,"twitter_title":null,"twitter_description":null,"meta_title":null,"meta_description":null,"email_subject":null,"frontmatter":null,"feature_image_alt":null,"feature_image_caption":null},{"id":"61fe29f1c7139e0001a71b3a","uuid":"46e0345d-f1ea-4a18-ab1c-1da88b2205d2","title":"YC Partners With Atomwise to Fund More Bio Companies","slug":"yc-partners-with-atomwise-to-fund-more-bio-companies","html":"<!--kg-card-begin: html--><p>In the last 10 years, the tools for studying biology have become much less expensive and more widely available. This has made it possible for new startups to do serious research right from the start, and it is leading to an explosion of biotech startups.</p>\n<p>One of the key tools that has brought down the cost of developing drugs is computational drug discovery. Until recently, the primary way drug companies found new drugs was by trying millions of chemical compounds, hoping one would work, and laboriously iterating their way to a drug. <a href=https://www.ycombinator.com/"https://www.atomwise.com//">Atomwise (which is a YC company) is able to do those experiments in simulation on a computer, testing billions of compounds dramatically cheaper, faster, and far beyond the capability of physical screening.</p>\n<p>About two years ago, Atomwise started the <a href=https://www.ycombinator.com/"http://www.atomwise.com/aims-awards//">Artificial Intelligence Molecular Screen (AIMS) Awards program</a>, which I think is a game changer. AIMS gives away Atomwise&#8217;s drug discovery service for free to researchers in academia. Today, when researchers at a university discover a promising opportunity for a new drug (in scientific terms, a &#8220;target&#8221;), they&#8217;re stuck in a catch-22. They need to raise funding to pay for drug discovery to find the right drug, but it&#8217;s hard to raise investment until they&#8217;ve found a compelling lead molecule! AIMS solves the catch-22.</p>\n<p>AIMS has already helped over 200 researchers discover small molecule leads in diverse areas, including oncology, infectious diseases, metabolic disorders, and neurology. I believe this is the tip of the iceberg, and AIMS can unlock thousands of promising therapeutics ideas that would otherwise never have been developed.</p>\n<p>Once researchers work with AIMS to develop drug candidates, the next step is to turn the research into a company. That&#8217;s where YC comes in. We&#8217;re going to work with Atomwise to give interested AIMS teams an expedited path to joining YC. For AIMS teams that want YC funding, we’ll guide them through the YC application process and prioritize their applications. For AIMS teams that we accept, we&#8217;ll invest in them, help them incorporate, and help them with the initial stages of commercialization &#8211; everything from figuring out their regulatory strategy to getting lab space.</p>\n<p>In addition, Atomwise is going to make the free drug discovery service they pioneered in the AIMS program available as a benefit to all YC companies. This should help any YC company to develop a small molecule program faster than any other existing option.</p>\n<p>We believe this is the golden age of drug discovery, and we’re thrilled to partner with Atomwise. The <a href=https://www.ycombinator.com/"https://atomwise.wpengine.com//">application deadline for Atomwise’s AIMS Awards program is May 31— and <a href=https://www.ycombinator.com/"https://www.ycombinator.com/apply//">YC applications</a> are always open.</p>\n<!--kg-card-end: html-->","comment_id":"1103627","feature_image":null,"featured":false,"visibility":"public","email_recipient_filter":"none","created_at":"2019-04-28T22:59:37.000-07:00","updated_at":"2021-10-20T10:55:11.000-07:00","published_at":"2019-04-28T22:59:37.000-07:00","custom_excerpt":null,"codeinjection_head":null,"codeinjection_foot":null,"custom_template":null,"canonical_url":null,"authors":[{"id":"61fe29e3c7139e0001a71097","name":"Jared Friedman","slug":"jared-friedman","profile_image":"/blog/content/images/2022/02/Jared.jpg","cover_image":null,"bio":"Jared is Managing Director, Software and Group Partner at YC. He was cofounder of Scribd, which was funded by Y Combinator in 2006 and grew to be one of the top 100 sites on the web.","website":null,"location":null,"facebook":null,"twitter":null,"meta_title":null,"meta_description":null,"url":"https://ghost.prod.ycinside.com/author/jared-friedman/"}],"tags":[{"id":"61fe29efc7139e0001a7117e","name":"Biotech","slug":"biotech","description":null,"feature_image":null,"visibility":"public","og_image":null,"og_title":null,"og_description":null,"twitter_image":null,"twitter_title":null,"twitter_description":null,"meta_title":null,"meta_description":null,"codeinjection_head":null,"codeinjection_foot":null,"canonical_url":null,"accent_color":null,"url":"https://ghost.prod.ycinside.com/tag/biotech/"},{"id":"61fe29efc7139e0001a71173","name":"YC News","slug":"yc-news","description":null,"feature_image":null,"visibility":"public","og_image":null,"og_title":null,"og_description":null,"twitter_image":null,"twitter_title":null,"twitter_description":null,"meta_title":null,"meta_description":null,"codeinjection_head":null,"codeinjection_foot":null,"canonical_url":null,"accent_color":null,"url":"https://ghost.prod.ycinside.com/tag/yc-news/"}],"primary_author":{"id":"61fe29e3c7139e0001a71097","name":"Jared Friedman","slug":"jared-friedman","profile_image":"https://ghost.prod.ycinside.com/content/images/2022/02/Jared.jpg","cover_image":null,"bio":"Jared is Managing Director, Software and Group Partner at YC. He was cofounder of Scribd, which was funded by Y Combinator in 2006 and grew to be one of the top 100 sites on the web.","website":null,"location":null,"facebook":null,"twitter":null,"meta_title":null,"meta_description":null,"url":"https://ghost.prod.ycinside.com/author/jared-friedman/"},"primary_tag":{"id":"61fe29efc7139e0001a7117e","name":"Biotech","slug":"biotech","description":null,"feature_image":null,"visibility":"public","og_image":null,"og_title":null,"og_description":null,"twitter_image":null,"twitter_title":null,"twitter_description":null,"meta_title":null,"meta_description":null,"codeinjection_head":null,"codeinjection_foot":null,"canonical_url":null,"accent_color":null,"url":"https://ghost.prod.ycinside.com/tag/biotech/"},"url":"https://ghost.prod.ycinside.com/yc-partners-with-atomwise-to-fund-more-bio-companies/","excerpt":"In the last 10 years, the tools for studying biology have become much less expensive and more widely available. This has made it possible for new startups to do serious research right from the start, and it is leading to an explosion of biotech startups.","reading_time":2,"access":true,"og_image":null,"og_title":null,"og_description":null,"twitter_image":null,"twitter_title":null,"twitter_description":null,"meta_title":null,"meta_description":null,"email_subject":null,"frontmatter":null,"feature_image_alt":null,"feature_image_caption":null},{"id":"638559cc3a008e000176edd4","uuid":"e7d13ed0-72da-46aa-a877-cb21bda20645","title":"YC Happy Hour at the JP Morgan Healthcare Conference","slug":"yc-happy-hour-at-jp-morgan-healthcare-conference","html":"<p>Join us for a happy hour during the JP Morgan Healthcare Conference. </p><p>If you’re a YC alum, an investor, industry leader, or are interested in starting a bio or healthcare company, we’d love to see you there.</p><p><strong>YC at JPM</strong><br>January 10 from 2:30 - 5 pm in San Francisco, CA<br>Appetizers and drinks will be served. <br><br>Space is limited, so sign up <a href=https://www.ycombinator.com/"https://docs.google.com/forms/d/e/1FAIpQLSdtMLHJC2orF1Ua8PAz4V20IZCeHTtTbNdESZtXU84QUPYL8w/viewform?usp=sf_link\%22>here by December 29 and we’ll send you a confirmation and location details by December 30.</p><!--kg-card-begin: html--><center>\n<a class=\"ycdc-retro-btn ycdc-retro-btn-gold mt-[-10px] ml-[13px]\" href=https://www.ycombinator.com/"https://docs.google.com/forms/d/e/1FAIpQLSdtMLHJC2orF1Ua8PAz4V20IZCeHTtTbNdESZtXU84QUPYL8w/viewform/" style=\"text-decoration: none;\" title=\"YC Happy Hour at JP Morgan Healthcare Conference\" target=\"_blank\">Sign Up</a>\n</center><!--kg-card-end: html-->","comment_id":"638559cc3a008e000176edd4","feature_image":"/blog/content/images/2022/11/BlogTwitter-Image-Template--31-.png","featured":true,"visibility":"public","email_recipient_filter":"none","created_at":"2022-11-28T17:01:00.000-08:00","updated_at":"2022-11-29T08:51:35.000-08:00","published_at":"2022-11-29T08:51:00.000-08:00","custom_excerpt":"Join us for a happy hour during the JP Morgan Healthcare Conference in San Francisco on January 10th. If you’re a YC alum, an investor, industry leader, or are interested in starting a bio or healthcare company, we’d love to see you there.","codeinjection_head":null,"codeinjection_foot":null,"custom_template":null,"canonical_url":null,"authors":[{"id":"61fe29e3c7139e0001a71072","name":"Surbhi Sarna","slug":"surbhi-sarna","profile_image":"/blog/content/images/2022/09/1563221214332.jpg","cover_image":null,"bio":"Surbhi is a group partner at Y Combinator. Prior to YC, Surbhi was CEO of nVision Medical, which was acquired by Boston Scientific.","website":null,"location":null,"facebook":null,"twitter":null,"meta_title":null,"meta_description":null,"url":"https://ghost.prod.ycinside.com/author/surbhi-sarna/"}],"tags":[{"id":"61fe29efc7139e0001a71179","name":"YC Events","slug":"yc-events","description":null,"feature_image":null,"visibility":"public","og_image":null,"og_title":null,"og_description":null,"twitter_image":null,"twitter_title":null,"twitter_description":null,"meta_title":null,"meta_description":null,"codeinjection_head":null,"codeinjection_foot":null,"canonical_url":null,"accent_color":null,"url":"https://ghost.prod.ycinside.com/tag/yc-events/"},{"id":"61fe29efc7139e0001a71173","name":"YC News","slug":"yc-news","description":null,"feature_image":null,"visibility":"public","og_image":null,"og_title":null,"og_description":null,"twitter_image":null,"twitter_title":null,"twitter_description":null,"meta_title":null,"meta_description":null,"codeinjection_head":null,"codeinjection_foot":null,"canonical_url":null,"accent_color":null,"url":"https://ghost.prod.ycinside.com/tag/yc-news/"},{"id":"6321041a51421000014435a2","name":"Healthcare","slug":"healthcare","description":null,"feature_image":null,"visibility":"public","og_image":null,"og_title":null,"og_description":null,"twitter_image":null,"twitter_title":null,"twitter_description":null,"meta_title":null,"meta_description":null,"codeinjection_head":null,"codeinjection_foot":null,"canonical_url":null,"accent_color":null,"url":"https://ghost.prod.ycinside.com/tag/healthcare/"},{"id":"61fe29efc7139e0001a71183","name":"Event","slug":"event","description":null,"feature_image":null,"visibility":"public","og_image":null,"og_title":null,"og_description":null,"twitter_image":null,"twitter_title":null,"twitter_description":null,"meta_title":null,"meta_description":null,"codeinjection_head":null,"codeinjection_foot":null,"canonical_url":null,"accent_color":null,"url":"https://ghost.prod.ycinside.com/tag/event/"},{"id":"61fe29efc7139e0001a7117e","name":"Biotech","slug":"biotech","description":null,"feature_image":null,"visibility":"public","og_image":null,"og_title":null,"og_description":null,"twitter_image":null,"twitter_title":null,"twitter_description":null,"meta_title":null,"meta_description":null,"codeinjection_head":null,"codeinjection_foot":null,"canonical_url":null,"accent_color":null,"url":"https://ghost.prod.ycinside.com/tag/biotech/"}],"primary_author":{"id":"61fe29e3c7139e0001a71072","name":"Surbhi Sarna","slug":"surbhi-sarna","profile_image":"https://ghost.prod.ycinside.com/content/images/2022/09/1563221214332.jpg","cover_image":null,"bio":"Surbhi is a group partner at Y Combinator. Prior to YC, Surbhi was CEO of nVision Medical, which was acquired by Boston Scientific.","website":null,"location":null,"facebook":null,"twitter":null,"meta_title":null,"meta_description":null,"url":"https://ghost.prod.ycinside.com/author/surbhi-sarna/"},"primary_tag":{"id":"61fe29efc7139e0001a71179","name":"YC Events","slug":"yc-events","description":null,"feature_image":null,"visibility":"public","og_image":null,"og_title":null,"og_description":null,"twitter_image":null,"twitter_title":null,"twitter_description":null,"meta_title":null,"meta_description":null,"codeinjection_head":null,"codeinjection_foot":null,"canonical_url":null,"accent_color":null,"url":"https://ghost.prod.ycinside.com/tag/yc-events/"},"url":"https://ghost.prod.ycinside.com/yc-happy-hour-at-jp-morgan-healthcare-conference/","excerpt":"Join us for a happy hour during the JP Morgan Healthcare Conference. ","reading_time":1,"access":true,"og_image":null,"og_title":null,"og_description":null,"twitter_image":null,"twitter_title":null,"twitter_description":null,"meta_title":null,"meta_description":null,"email_subject":null,"frontmatter":null,"feature_image_alt":null,"feature_image_caption":null}]},"url":"/blog/shasqi-first-in-human-clinical-trials","version":"86a82864a2e98321858efc8147c8b7f9287218a4","encryptHistory":false,"clearHistory":false,"rails_context":{"railsEnv":"production","inMailer":false,"i18nLocale":"en","i18nDefaultLocale":"en","href":"https://www.ycombinator.com/blog/shasqi-first-in-human-clinical-trials","location":"/blog/shasqi-first-in-human-clinical-trials","scheme":"https","host":"www.ycombinator.com","port":null,"pathname":"/blog/shasqi-first-in-human-clinical-trials","search":null,"httpAcceptLanguage":"en, *","applyBatchLong":"Spring 2026","applyBatchShort":"X2026","applyDeadlineShort":"February 9","ycdcRetroMode":true,"currentUser":null,"serverSide":true},"id":"ycdc_new/pages/BlogPage-react-component-d244c720-7fde-4441-8884-2cba6a6baf37","server_side":true}" data-reactroot="">